Cargando…
Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release
The non-steroid anti-inflammatory drug ketoprofen (KP) as a model molecule is encapsulated in different poly(lactide-co-glycolide) (PLGA) nanostructured particles, using Tween20 (TWEEN) and Pluronic F127 (PLUR) as stabilizers to demonstrate the design of a biocompatible colloidal carrier particles w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223903/ https://www.ncbi.nlm.nih.gov/pubmed/37242597 http://dx.doi.org/10.3390/pharmaceutics15051355 |
_version_ | 1785050051175776256 |
---|---|
author | Varga, Norbert Bélteki, Rita Juhász, Ádám Csapó, Edit |
author_facet | Varga, Norbert Bélteki, Rita Juhász, Ádám Csapó, Edit |
author_sort | Varga, Norbert |
collection | PubMed |
description | The non-steroid anti-inflammatory drug ketoprofen (KP) as a model molecule is encapsulated in different poly(lactide-co-glycolide) (PLGA) nanostructured particles, using Tween20 (TWEEN) and Pluronic F127 (PLUR) as stabilizers to demonstrate the design of a biocompatible colloidal carrier particles with highly controllable drug release feature. Based on TEM images the formation of well-defined core-shell structure is highly favorable using nanoprecipitation method. Stabile polymer-based colloids with ~200–210 nm hydrodynamic diameter can be formed by successful optimization of the KP concentration with the right choice of stabilizer. Encapsulation efficiency (EE%) of 14–18% can be achieved. We clearly confirmed that the molecular weight of the stabilizer thus its structure greatly controls the drug release from the PLGA carrier particles. It can be determined that ~20% and ~70% retention is available with the use of PLUR and TWEEN, respectively. This measurable difference can be explained by the fact that the non-ionic PLUR polymer provides a steric stabilization of the carrier particles in the form of a loose shell, while the adsorption of the non-ionic biocompatible TWEEN surfactant results in a more compact and well-ordered shell around the PLGA particles. In addition, the release property can be further tuned by decreasing the hydrophilicity of PLGA by changing the monomer ratio in the range of ~20–60% (PLUR) and 70–90% (TWEEN). |
format | Online Article Text |
id | pubmed-10223903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102239032023-05-28 Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release Varga, Norbert Bélteki, Rita Juhász, Ádám Csapó, Edit Pharmaceutics Article The non-steroid anti-inflammatory drug ketoprofen (KP) as a model molecule is encapsulated in different poly(lactide-co-glycolide) (PLGA) nanostructured particles, using Tween20 (TWEEN) and Pluronic F127 (PLUR) as stabilizers to demonstrate the design of a biocompatible colloidal carrier particles with highly controllable drug release feature. Based on TEM images the formation of well-defined core-shell structure is highly favorable using nanoprecipitation method. Stabile polymer-based colloids with ~200–210 nm hydrodynamic diameter can be formed by successful optimization of the KP concentration with the right choice of stabilizer. Encapsulation efficiency (EE%) of 14–18% can be achieved. We clearly confirmed that the molecular weight of the stabilizer thus its structure greatly controls the drug release from the PLGA carrier particles. It can be determined that ~20% and ~70% retention is available with the use of PLUR and TWEEN, respectively. This measurable difference can be explained by the fact that the non-ionic PLUR polymer provides a steric stabilization of the carrier particles in the form of a loose shell, while the adsorption of the non-ionic biocompatible TWEEN surfactant results in a more compact and well-ordered shell around the PLGA particles. In addition, the release property can be further tuned by decreasing the hydrophilicity of PLGA by changing the monomer ratio in the range of ~20–60% (PLUR) and 70–90% (TWEEN). MDPI 2023-04-28 /pmc/articles/PMC10223903/ /pubmed/37242597 http://dx.doi.org/10.3390/pharmaceutics15051355 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Varga, Norbert Bélteki, Rita Juhász, Ádám Csapó, Edit Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title | Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title_full | Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title_fullStr | Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title_full_unstemmed | Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title_short | Core-Shell Structured PLGA Particles Having Highly Controllable Ketoprofen Drug Release |
title_sort | core-shell structured plga particles having highly controllable ketoprofen drug release |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223903/ https://www.ncbi.nlm.nih.gov/pubmed/37242597 http://dx.doi.org/10.3390/pharmaceutics15051355 |
work_keys_str_mv | AT varganorbert coreshellstructuredplgaparticleshavinghighlycontrollableketoprofendrugrelease AT beltekirita coreshellstructuredplgaparticleshavinghighlycontrollableketoprofendrugrelease AT juhaszadam coreshellstructuredplgaparticleshavinghighlycontrollableketoprofendrugrelease AT csapoedit coreshellstructuredplgaparticleshavinghighlycontrollableketoprofendrugrelease |